Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 7/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29419125 | 1.00 | MKNK1 (0.50) | MKNK1MKNK2EGFRDYRK1AFLT3 | |
| SCHEMBL30337437 | 0.83 | DYRK1A (0.43) | MKNK1MKNK2EGFRDYRK1AKDM4E | |
| SCHEMBL28987624 | 0.83 | DYRK1A (0.43) | MKNK1MKNK2EGFRDYRK1AKDM4E | |
| SCHEMBL30337162 | 0.83 | DYRK1A (0.46) | MKNK1MKNK2EGFRDYRK1ALMNA | |
| SCHEMBL28384419 | 0.83 | DYRK1A (0.46) | MKNK1MKNK2EGFRDYRK1ALMNA | |
| SCHEMBL19532488 | 0.82 | MKNK2 (0.54) | MKNK1MKNK2DYRK1ACDK2 | |
| SCHEMBL17553630 | 0.82 | DYRK1A (0.68) | DYRK1AFLT3CDK5CDK5R1CCNT1 | |
| SCHEMBL5750318 | 0.82 | CDC7 (0.60) | MKNK1MKNK2EGFRDYRK1ACDK5 | |
| SCHEMBL28987594 | 0.82 | CDK5 (0.51) | MKNK1MKNK2EGFRDYRK1AFLT3 | |
| SCHEMBL28939744 | 0.82 | EGFR (0.52) | MKNK1MKNK2EGFRDYRK1AFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692075-A1 | USE OF A MECHANICAL FORCE IN THE PROCESS OF PREPARATION OF OSIMERTINIB | Université de Montpellier (FR) | 2026-02-11 | — | — | EP | claimed |
| CN-107727773-B | Method for detecting purity of oxitinib mesylate by adopting liquid chromatography | 中山奕安泰医药科技有限公司 | 2020-08-18 | — | — | CN | claimed |
| CN-104844580-B | Pyrimidines, its preparation method and medical usage | 中国药科大学 | 2017-10-20 | — | — | CN | claimed |
| EP-4692075-A1 | USE OF A MECHANICAL FORCE IN THE PROCESS OF PREPARATION OF OSIMERTINIB | Université de Montpellier (FR) | 2026-02-11 | — | — | EP | disclosed |
| US-20250275968-A1 | INHIBITORS OF TAU PROTEINS | DEUTSCHES ZENTRUM FÜR NEURODEGENERATIVE ERKRANKUNGEN E.V. (DE) | 2025-09-04 | — | — | US | disclosed |
| US-20250250255-A1 | IMPROVED PROCESS FOR THE MANUFACTURE OF OSIMERTINIB | ASTRAZENECA AB (SE) | 2025-08-07 | — | — | US | disclosed |
| US-20250154128-A1 | A PROCESS FOR MAKING OSIMERTINIB | SYNTHON B.V. (NL) | 2025-05-15 | — | — | US | disclosed |
| EP-4518858-A1 | INHIBITORS OF TAU PROTEINS | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DE) | 2025-03-12 | — | — | EP | disclosed |
| EP-4504718-A1 | IMPROVED PROCESS FOR THE MANUFACTURE OF OSIMERTINIB | Astrazeneca AB (SE) | 2025-02-12 | — | — | EP | disclosed |
| US-20240425476-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2024-12-26 | — | — | US | disclosed |
| US-20240382599-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-11-21 | — | — | US | disclosed |
| US-20130053409-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2013-02-28 | — | — | US | disclosed |
| US-20130053409-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2013-02-28 | — | — | US | disclosed |
| US-20130053409-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2013-02-28 | — | — | US | disclosed |
| WO-2013014448-A1 | 2 - (2, 4, 5 - SUBSTITUTED -ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013014448-A1 | 2 - (2, 4, 5 - SUBSTITUTED -ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2013-01-31 | — | — | WO | disclosed |
| CN-101547917-A | Substituted pyrimidines and their use as JNK modulators | HOFFMANN LAROCHE (CH) | 2009-09-30 | — | — | CN | disclosed |
| US-20080146565-A1 | JNK modulators | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
| US-20080146565-A1 | JNK modulators | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
| US-20080146565-A1 | JNK modulators | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053409-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE COMPOUNDS | EGFR, ERBB2, ERBB3 | MKNK1 2749/4885MKNK2 2846/4885EGFR 1/4885 |
| US-20240382599-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | TBK1, EGFR, CBL | MKNK1 499/4885MKNK2 551/4885EGFR 2/4885 |
| US-20250275968-A1 | INHIBITORS OF TAU PROTEINS | MAPT, PSEN2, PSEN1 | MKNK1 542/4885MKNK2 408/4885EGFR 4305/4885 |
| US-20080146565-A1 | JNK modulators | MAPKAPK2, MAPKAPK3, MAP3K10 | MKNK1 38/4885MKNK2 34/4885EGFR 949/4885 |
| US-20250250255-A1 | IMPROVED PROCESS FOR THE MANUFACTURE OF OSIMERTINIB | ALK, ROS1, ABL1 | MKNK1 259/4885MKNK2 285/4885EGFR 42/4885 |
| US-20240425476-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | EGFR, ERBB2, ERBB3 | MKNK1 2749/4885MKNK2 2846/4885EGFR 1/4885 |
| US-20250154128-A1 | A PROCESS FOR MAKING OSIMERTINIB | ROS1, JAK1, EGFR | MKNK1 402/4885MKNK2 510/4885EGFR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.